What is Pfizer's braftovi/mektovi — revenues:?

Pfizer (PFE) reported braftovi/mektovi — revenues: of $174M in Q1 2026.

How has Pfizer's braftovi/mektovi — revenues: changed year-over-year?

Pfizer's braftovi/mektovi — revenues: increased by 27.9% year-over-year, from $136M to $174M.

What is the long-term trend for Pfizer's braftovi/mektovi — revenues:?

Over 3 years (2022 to 2025), Pfizer's braftovi/mektovi — revenues: has grown at a 16.3% compound annual growth rate (CAGR), from $456M to $717M.

Pfizer PFE Braftovi/Mektovi — Revenues:

Other product segments

Eliquis

$2.17B+12.6%

Prevnar Family

$1.69B+1.8%

Vyndaqel family

$1.6B+7.8%

Ibrance

$1.01B+3.2%

All Other Hospital and Biosimilars

$953M—

All other Primary Care

$654M+7.4%

Padcev

$591M+38.7%

All other Specialty Care

$579M+19.1%

Xtandi

$444M-3.1%

Oncology Biosimilars

$409M+54.9%

Royalty

$396M+28.6%

All other Oncology

$376M-0.3%

Nurtec ODT/Vydura

$353M+42.3%

Lorbrena

$305M+37.4%

Pfizer CentreOne

$289M+5.9%

Comirnaty

$232M-58.9%

Paxlovid

$219M-69.9%

Inlyta

$214M-2.3%

Sulperazon (Outside the U.S. and Canada)

$199M+21.3%

Adcetris

$190M-12.8%

Inflectra

$182M—

Abrysvo

$180M+37.4%

Xeljanz

$180M+40.6%

Zavicefta (Outside the U.S. and Canada)

$150M+11.1%

Enbrel (Outside the U.S. and Canada)

$138M-1.4%

Bosulif

$129M-14.6%

Octagam

$122M—

Tukysa

$122M+19.6%

Zithromax

$112M-29.1%

Orgovyx

$109M—

Genotropin

$93M—

FSME-IMMUN/TicoVac

$81M—

Elrexfio

$80M+33.3%

Cibinqo

$76M+31.0%

Talzenna

$50M+25.0%

Tivdak

$33M0.0%

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+4.9%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$138.21B-3.7%

Enterprise value$200.88B-1.3%

P/E11.4×—

P/S2.2×-0.1×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

FCF margin18%+8.8pp

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's braftovi/mektovi — revenues:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's braftovi/mektovi — revenues:?: Pfizer (PFE) reported braftovi/mektovi — revenues: of $174M in Q1 2026.
How has Pfizer's braftovi/mektovi — revenues: changed year-over-year?: Pfizer's braftovi/mektovi — revenues: increased by 27.9% year-over-year, from $136M to $174M.
What is the long-term trend for Pfizer's braftovi/mektovi — revenues:?: Over 3 years (2022 to 2025), Pfizer's braftovi/mektovi — revenues: has grown at a 16.3% compound annual growth rate (CAGR), from $456M to $717M.